

Resource Summary Report

Generated by [RRID](#) on Aug 11, 2026

Mouse Anti-p44 / 42 MAP Kinase Monoclonal Antibody, Unconjugated, Clone L34F12

RRID:AB_390780

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4696, RRID:AB_390780

Antibody Information

URL: http://antibodyregistry.org/AB_390780

Proper Citation: Cell Signaling Technology Cat# 4696, RRID:AB_390780

Target Antigen: p44 / 42 MAP Kinase

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: W, IHC-P, IF-IC, F. Consolidation on 9/2016: AB_10694988.

Antibody Name: Mouse Anti-p44 / 42 MAP Kinase Monoclonal Antibody, Unconjugated, Clone L34F12

Description: This monoclonal targets p44 / 42 MAP Kinase

Target Organism: monkey, rat, simian, mouse, human

Clone ID: Clone L34F12

Antibody ID: AB_390780

Vendor: Cell Signaling Technology

Catalog Number: 4696

Alternative Catalog Numbers: 4696S

Record Creation Time: 20250819T232959+0000

Record Last Update: 20250820T053135+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-p44 / 42 MAP Kinase Monoclonal Antibody, Unconjugated, Clone L34F12.

No alerts have been found for Mouse Anti-p44 / 42 MAP Kinase Monoclonal Antibody, Unconjugated, Clone L34F12.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 150 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Wei X, et al. (2026) Abrogation of Oncogenic RAS Signaling by a RAS(ON) Inhibitor Doublet Primes Immune-Refractory KRASG12C-Mutant NSCLC for Immune Checkpoint Blockade. Cancer discovery, 16(6), 1152.

O'Toole KT, et al. (2026) Identification and characterization of BRAF?TP53 interactions in melanoma. Cell reports, 45(4), 117078.

Postlmayr A, et al. (2026) Functionally distinct ALK and ROS1 fusions detected in infant-type hemispheric gliomas converge on STAT3 and SHP2 activation. Cell reports, 45(3), 117046.

Luo YE, et al. (2026) Resident mesenchymal progenitor cells require autocrine IGF-I in homeostatic and regenerating skeletal muscle. Stem cell reports, 21(7), 102973.

Zhang Y, et al. (2026) Paneth-like transition drives resistance to dual targeting of KRAS and EGFR in colorectal cancer. Cancer cell, 44(1), 77.

Daniali M, et al. (2026) It's Not Rewarding for Mitochondria: Dopamine-Induced Mitochondrial Dysfunction Activates cGAS-STING to Drive IL-6 Secretion in Macrophages. bioRxiv : the preprint server for biology.

Xie L, et al. (2026) Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor. Cancer discovery, 16(5), 895.

Mitra T, et al. (2026) MEK-dependent bioenergetic demand drives terminal CD8+ T cell exhaustion. Immunity.

Lee SJ, et al. (2026) Hypoxia restores the acidosis-induced inhibition of cancer cell dissemination. Cell reports, 45(2), 116970.

Zorn A, et al. (2026) The selective degradation of PDE4B shortform, using a PROTAC, leads to inhibition of several hallmarks of cancer in HCT116 cells. British journal of

pharmacology.

Lee EJ, et al. (2026) JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(9), 1835.

Fan H, et al. (2026) Dynamic control of Raf-ERK signaling modulates neuronal activity across biological scales. *bioRxiv : the preprint server for biology*.

Maqoud F, et al. (2026) Modulation of KATP channels by diazoxide preserves mitochondrial function and barrier integrity under staurosporine-induced epithelial stress. *British journal of pharmacology*, 183(12), 3213.

Grandl G, et al. (2026) FGF21 reduces ER stress by enhancing the unfolded protein and integrated stress responses through increased sulfide signaling. *Cell metabolism*, 38(7), 1354.

Derdikman Ofir Y, et al. (2026) Lnk Governs chemokine-directed trafficking of CD8+ T cells in melanoma. *Molecular therapy. Oncology*, 34(3), 201288.

Kremmyda P, et al. (2026) SHP2 regulates VEGFR2 Y1175/PLC γ signaling to impair tumor endothelial barrier stability. *iScience*, 29(2), 114784.

Sang B, et al. (2026) Disrupted molecular glue complex drives RAS inhibitor resistance. *Cell*, 189(10), 2918.

Lacroix R, et al. (2026) Embryonic exposure to environmental levels of roundup affects neurodevelopment in zebrafish. *Journal of the Endocrine Society*, 10(5), bvag067.

Li Y, et al. (2026) Tuberostemonine ameliorates Alzheimer's disease pathology by suppression of the p38 MAPK signaling pathway. *iScience*, 29(8), 116887.

Espinosa de Los Monteros-Zúñiga A, et al. (2025) The biased OTR ligands -atosiban and carbetocin- differentially inhibit early or late formalin-induced nociception in rats. *Neuropharmacology*, 275, 110487.